TD Cowen Raises TMO Price Target to $810

TD Cowen reiterated its Buy rating on Thermo Fisher Scientific Inc. (NYSE: TMO) while raising its price target to $810.00 from $760.00 on October 22, 2026. The research note points to continued confidence in the life sciences firm as shares trade near their recent ranges.

TMO Thermo Fisher Scientific Inc.

$694.02 ▲ +17.46% year to date

1M 3M YTD

Daily close · Oct 21, 2026

TD Cowen's Call on Thermo Fisher Scientific

In its October 22, 2026 research note, TD Cowen maintained a Buy rating on the company and pushed its target higher to $810.00 from the prior target of $760.00. Several other major firms updated their views on the same day, including Barclays maintaining an Overweight rating with a target moved to $775.00 from $750.00, and RBC Capital keeping a Sector Perform rating while lifting its target from $580.00 to $730.00. Stifel maintained its Buy rating and raised its target to $775.00 from $650.00, while Baird kept an Outperform rating and pushed its target to $756.00 from $723.00. Across the broader Wall Street analyst community, the stock holds a consensus strong buy rating with an average target price of $706.69 across 26 analyst opinions.

Other Institutional Activity in Thermo Fisher Scientific

Franklin Resources, Inc. adjusted its position in the firm, growing its holdings by 458,515 shares to end with 7,271,514 shares valued at about $4.93 billion as of June 30, 2026. That adjustment marked a 6.7% increase for the fund.

Thermo Fisher Scientific Inc. Stock Up 1.0%

Shares of Thermo Fisher Scientific recently traded around $694.02 as of October 22, 2026, up about 2.3% from the session's close of $678.43. The stock sits about 1.7% below its 52-week high of $705.79 and rests comfortably above its 50-day moving average of $641.93 and its 200-day moving average of $548.71. The company carries a market capitalization of roughly $256.61 billion, a price-to-earnings ratio of 36.60, and a forward P/E of 25.06.

Recent Earnings

Thermo Fisher Scientific generated $47.35 billion in trailing twelve month revenue and posted a trailing EPS of $18.96. The healthcare provider logged a net profit margin of 14.9% and a return on equity of 13.4%. The company's next quarterly financial update is scheduled for release on January 28, 2027.

Dividend

Thermo Fisher Scientific pays an annual dividend of $1.88 per share, giving investors a dividend yield of 0.27%. The company maintains a dividend payout ratio of 9.7% of its earnings.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Company insiders completed several transactions ahead of the analyst updates. On August 19, 2026, officer Lisa P Britt sold 11,440 shares at an average price of $613.12 for a total value of $7.01 million. Chief Executive Officer Marc N Casper sold 20,000 shares on August 21, 2026, valued at $12.56 million, followed by an additional sale of 275 shares valued at $172,439 on August 24, 2026. President Gianluca Pettiti sold 4,133 shares at $614.38 on August 31, 2026, totaling roughly $2.54 million.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services around the world. Headquartered in Waltham, Massachusetts, and employing 125,000 people, the company operates across four core segments to support research, clinical trials, and diagnostics for healthcare clients globally.

Bottom Line

Investors tracking Thermo Fisher Scientific will look toward the upcoming earnings report on January 28, 2027, to see how revenue growth and profit margins track against analyst projections. Market participants should also monitor further institutional filings and shifting price targets as shares trade near their 52-week highs.